Posted on

Did You Know? The Currently Marketed Vaxx for CV-19 Is Actually Still In Clinical Trials

 

 

Did You Know? The Currently Marketed Vaxx for CV-19 Is Actually Still In Clinical Trials

Governments’ experimental CV-19 injection is an mRNA modification originally developed as an individualized skin cancer therapy. Estimated study completion date: May 15, 2023.

Politicians and unelected bureaucrats have zero authority to mandate the public participate in unsafe medical experiments.

This unnecessary and dangerous medical intervention has proven not to be safe or effective.

 


 

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

 

Brief Summary:

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.

The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.

The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:

  • As a 2-dose (separated by 21 days) schedule;
  • At various different dose levels in Phase 1;
  • As a booster;
  • In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).

Link To_Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43998 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Actual Study Start Date : April 29, 2020
Estimated Primary Completion Date : May 15, 2023
Estimated Study Completion Date : May 15, 2023

 

Link To_Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals


 

LINK TO THE UNITY PROJECT

 

According to VAERS (Vaccine Adverse Effects Reporting System), excluding “foreign reports” to VAERS 9,136 deaths were reported in the U.S. between Dec. 14, 2020, and Dec. 3, 2021 in America. 

https://openvaers.com/

https://vaers.hhs.gov/

— Therefore, the vaccines have significant risks.

According to the WHO, there have been at least 2,457,386 adverse events world-wide. This is over 1,000,000 more cases than all adverse events reported over the last 53 years of all vaccines administered since 1968 combined (www.vigiaccess.org). Search Trade Name of Drug: COVID-19 Vaccine

— Therefore, the vaccines have significant risks.

The Unity Project | Do Not Comply: Nullify

#NotSafe #NotEffective